HEALTHCARE ECONOMICS PUBLICATIONS & ABSTRACTS

Healthcare Economics Data


Evidence / Healthcare Economics

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van โ€™t Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrintยฎ) to guide chemotherapy Read More

Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective

PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguรญ M.ร., Crespo C., Cortรฉs J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More

Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer

PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773โ€“3779 AUTHORS: V.P. Retรจl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were โ‚ฌ26,786 for the 70-gene and โ‚ฌ29,187 for AO. The Read More

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chรฉreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(ยฎ) and MammaPrint. Studies of both tests provided evidence Read More